Arcturus reports Q2 2026 results, regains KOSTAIVE rights from CSL Seqirus
Company says Phase 3 decision on cystic fibrosis candidate ARCT-032 is expected in Q4 2026, while ARCT-810 dosing has finished with data due later this quarter.
SEC filing
Latest
2 stories